Csl Ltd (CSLLY) 44.7100 $CSLLY
Seqirus Commemorates 100 Years of Parent Company, CSL, Delivering on its Promise to Develop Innovative Therapies
PR Newswire Europe - Mon Apr 25, 7:01AM CDT
Seqirus today commemorated with parent company, CSL Limited, 100 years of developing and delivering innovative therapies, including influenza vaccines and treatments that protect and save lives of people with serious and chronic medical conditions. To mark this milestone, CSL announced a A$25 million R&D Fellowship program for early stage and translational research.
Neutropenia Pipeline Market Reviewed for H2 2015
PR Newswire - Thu Mar 10, 8:00PM CST
The "Neutropenia - Pipeline Review, H2 2015" market research report provides an overview of the Neutropenia's therapeutic pipeline. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
CHRS: 25.39 (+0.82)
Haemophilus influenzae Type B Infections Pipeline Review, H2 2015
M2 - Thu Jan 28, 3:50AM CST
Research and Markets (http://www.researchandmarkets.com/research/x4kxq2/haemophilus) has announced the addition of the "Haemophilus influenzae Type B Infections - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Haemophilus influenzae Type B Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Haemophilus influenzae Type B Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Haemophilus influenzae Type B Infections Overview - Therapeutics Development - Pipeline Products for Haemophilus influenzae Type B Infections - Overview - Pipeline Products for Haemophilus influenzae Type B Infections - Comparative Analysis - Haemophilus influenzae Type B Infections - Therapeutics under Development by Companies - Haemophilus influenzae Type B Infections - Therapeutics under Investigation by Universities/Institutes - Haemophilus influenzae Type B Infections - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Haemophilus influenzae Type B Infections - Products under Development by Companies - Haemophilus influenzae Type B Infections - Products under Investigation by Universities/Institutes - Haemophilus influenzae Type B Infections - Companies Involved in Therapeutics Development - Beijing Minhai Biotechnology Co., Ltd - Biological E. Limited - CSL Limited - Daiichi Sankyo Company, Limited - Indian Immunologicals Limited - LG Life Science LTD. - Nuron Biotech, Inc. - Panacea Biotec Limited - Sanofi Pasteur SA - Sinovac Biotech Ltd. - Zydus Cadila Healthcare Limited For more information visit http://www.researchandmarkets.com/research/x4...aemophilus
SVA: 5.90 (+0.05)
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline Review, H2 2015
M2 - Wed Jan 27, 8:33AM CST
Research and Markets (http://www.researchandmarkets.com/research/hfx77x/hereditary) has announced the addition of the "Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Overview - Therapeutics Development - Pipeline Products for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Overview - Pipeline Products for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Comparative Analysis - Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Therapeutics under Development by Companies - Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Therapeutics under Investigation by Universities/Institutes - Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Products under Development by Companies - Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Products under Investigation by Universities/Institutes - Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Companies Involved in Therapeutics Development - Arrowhead Research Corporation - BioCryst Pharmaceuticals, Inc. - Cevec Pharmaceuticals GmbH - CSL Limited - Dyax Corp. - Global Blood Therapeutics, Inc. - iBio, Inc. - Isis Pharmaceuticals, Inc. - Pharming Group N.V. - ProMetic Life Sciences Inc. - Ra Pharmaceuticals, Inc. - Shire Plc For more information visit http://www.researchandmarkets.com/research/hfx77x/hereditary
GBT: 17.88 (+0.27), BCRX: 3.62 (+0.16), ISIS: 57.56 (-0.28), ARWR: 5.96 (-0.02), SHPG: 194.12 (+2.69), IBIO: 0.61 (-0.02), DYAX: 38.04 (-0.37)
Hemophilia A Therapeutics Pipeline Review 2015
M2 - Fri Jan 22, 6:00AM CST
Research and Markets (http://www.researchandmarkets.com/research/5rtzx4/hemophilia_a) has announced the addition of the "Hemophilia A - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Hemophilia A, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hemophilia A and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Hemophilia A Overview - Therapeutics Development - Pipeline Products for Hemophilia A - Overview - Pipeline Products for Hemophilia A - Comparative Analysis - Hemophilia A - Therapeutics under Development by Companies - Hemophilia A - Therapeutics under Investigation by Universities/Institutes - Hemophilia A - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Hemophilia A - Products under Development by Companies - Hemophilia A - Products under Investigation by Universities/Institutes - Hemophilia A - Companies Involved in Therapeutics Development - Alnylam Pharmaceuticals, Inc. - Amarna Therapeutics B.V. - Apitope International NV - AstraZeneca Plc - Baxalta Incorporated - Bayer AG - Biogen, Inc. - BioMarin Pharmaceutical Inc. - Catalyst Biosciences, Inc. - Celtic Pharmaceutical Holdings L.P. - CSL Limited - DBV Technologies S.A. - Dimension Therapeutics, Inc. - Dong-A Socio Group - Emergent BioSolutions Inc. - EpiVax, Inc. - Expression Therapeutics LLC - F. Hoffmann-La Roche Ltd. - Green Cross Corporation - Inbiopro Solutions Pvt. Ltd. - Lentigen Technology, Inc. - mAbxience S.A. - Novo Nordisk A/S - OPKO Health, Inc. - Pfizer Inc. - Pharming Group N.V. - rEVO Biologics, Inc. - Sangamo BioSciences, Inc. - Selecta Biosciences, Inc. - SK Chemicals Co., Ltd. - Spark Therapeutics, Inc. - The International Biotechnology Center (IBC) Generium - uniQure N.V. For more information visit http://www.researchandmarkets.com/research/5r...mophilia_a
BMRN: 99.42 (+1.22), EBS: 33.39 (+0.54), PFE: 36.89 (+0.22), SGMO: 6.33 (+0.17), RBIO: (), DMTX: 7.12 (-0.14), NVO: 56.97 (+0.43), OPK: 9.95 (+0.06), ONCE: 57.94 (+2.55), AZN: 34.14 (-0.15), CBIO: 1.49 (unch), BXLT: 46.02 (-0.18)
Neutropenia Therapeutics Pipeline Review, H2 2015
M2 - Mon Jan 18, 5:43AM CST
Research and Markets (http://www.researchandmarkets.com/research/4ffs34/neutropenia) has announced the addition of the "Neutropenia - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Neutropenia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Neutropenia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Neutropenia Overview - Therapeutics Development - Pipeline Products for Neutropenia - Overview - Pipeline Products for Neutropenia - Comparative Analysis - Neutropenia - Therapeutics under Development by Companies - Neutropenia - Therapeutics under Investigation by Universities/Institutes - Neutropenia - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Neutropenia - Products under Development by Companies - Neutropenia - Products under Investigation by Universities/Institutes - Neutropenia - Companies Involved in Therapeutics Development - Apotex, Inc. - Biocon Limited - Biogenomics Limited - Cellerant Therapeutics, Inc. - Coherus BioSciences, Inc. - CSL Limited - Dr. Reddy's Laboratories Limited - Inbiopro Solutions Pvt. Ltd. - Ligand Pharmaceuticals, Inc. - NAL Pharmaceuticals Ltd. - Prolong Pharmaceuticals - Richter Gedeon Nyrt. - Sandoz International GmbH - Therapeutic Proteins International, LLC - Toko Pharmaceutical Industries Co., Ltd. - USV Limited For more information visit http://www.researchandmarkets.com/research/4f...eutropenia
CHRS: 25.39 (+0.82)
Global Blood Plasma Market Growth of 10.54% CAGR by 2020 - Analysis, Technologies & Forecasts Report 2015-2020
M2 - Mon Jan 18, 5:29AM CST
Research and Markets (http://www.researchandmarkets.com/research/q4rkcg/global_blood) has announced the addition of the "Global Blood Plasma Market: Trends, Opportunities and Forecasts (2015-2020) - (By Market Segment, Type of Blood Plasma -IVIG, Albumin, Factor VIII, By Region-North America, Europe, APAC, Market Entry Strategies for Global Players)" report to their offering. According to this research report the global blood plasma market is projected to exhibit a CAGR of 10.54% during 2015 - 2020. Few of the leading companies operating in blood plasma market in world include CSL Behring, Baxter, Grifols SA and Octapharma, etc. Benefits of this Report: - To gain an in-depth understanding of Global Blood Plasma Market - To identify the on-going trends and anticipated growth in the next five years - To help industry consultants, blood plasma manufacturers, suppliers and distributors align their market-centric strategies - To gain insights on the prevalent market entry strategies in blood plasma market for domestic as well as foreign companies - To obtain research based business decision and add weight to presentations and marketing material Companies Mentioned: - AMAG Pharmaceuticals, Inc. - Antares Pharma Inc - Baxter International Inc - BioDelivery Sciences International, Inc. - Biota Pharmaceuticals, Inc. - CSL Ltd. - Cipla - Emergent BioSolutions, Inc. - Grifols S.A - Octopharma Report Structure: 1. Research Methodology 2. Product Overview 3. Executive Summary 4. Global Blood Plasma Market: An Analysis 5. North America Blood Plasma Market: Size, Growth and Forecast 6. APAC Blood Plasma Market: Size, Growth and Forecast 7. Europe Blood Plasma Market: Size, Growth and Forecast 8. RoW Blood Plasma Market: Size, Growth and Forecast 9. Blood Plasma Market Trends 10. Global Blood Plasma Market Dynamics 11. Blood Plasma Market: Policy and Regulatory Landscape 12. Blood Plasma Market: Value Chain Analysis 13. Blood Plasma Trade Data Analysis 14. Blood Plasma Market: Porter's Five Force Analysis 15. Blood Plasma Market: Competitive landscape 16. Global Blood Plasma Market: Company Profiles 17. Strategic Recommendations For more information visit http://www.researchandmarkets.com/research/q4...obal_blood
BDSI: 2.55 (+0.20), EBS: 33.39 (+0.54), BOTA: 1.55 (-0.04), BAX: 48.02 (-0.20), AMAG: 26.53 (-0.06), ATRS: 1.00 (-0.02)
CSL Limited - Product Pipeline Market Review - 2015: Latest Report By Radiant Insights, Inc
M2 - Mon Jan 11, 4:45AM CST
Radiantinsights.com has include "CSL Limited - Product Pipeline Review - 2015" to their Database.
Diabetic Nephropathy Pipeline Review, H2 2015 - Analysis & Opportunities
M2 - Tue Dec 29, 5:07AM CST
Research and Markets (http://www.researchandmarkets.com/research/4pj8km/diabetic) has announced the addition of the "Diabetic Nephropathy - Pipeline Review, H2 2015" report to their offering. The report Diabetic Nephropathy - Pipeline Review, H2 2015', provides an overview of the Diabetic Nephropathy's therapeutic pipeline. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - The report provides a snapshot of the global therapeutic landscape of Diabetic Nephropathy - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Diabetic Nephropathy and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Diabetic Nephropathy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Benefits of this Report: - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Diabetic Nephropathy - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Diabetic Nephropathy pipeline depth and focus of Indication therapeutics Companies Mentioned Include: - AbbVie Inc. - Aerpio Therapeutics, Inc. - Antisense Therapeutics Limited - Astellas Pharma Inc. - AstraZeneca Plc - Bayer AG - BiOrion Technologies B.V. - Cellmid Limited - ChemoCentryx, Inc. - Concert Pharmaceuticals, Inc. - CSL Limited - GlaxoSmithKline Plc - Glucox Biotech AB - Pfizer Inc. - PhytoHealth Corporation - ProMetic Life Sciences Inc. - Serodus ASA - Shire Plc - Takeda Pharmaceutical Company Limited - Tobira Therapeutics, Inc. - Torrent Pharmaceuticals Limited - Vascular Pharmaceuticals, Inc. - Vicore Pharma AB - XOMA Corporation For more information visit http://www.researchandmarkets.com/research/4pj8km/diabetic
PFE: 36.89 (+0.22), GSK: 45.07 (-0.11), CNCE: 11.49 (-0.28), AZN: 34.14 (-0.15), SHPG: 194.12 (+2.69), CCXI: 4.70 (+0.01), ABBV: 66.23 (+1.51), TBRA: 4.31 (+0.04), XOMA: 0.67 (+0.09)
Orthomyxoviridae Infections Global Clinical Trials Review, H2, 2014
M2 - Wed Dec 23, 6:00AM CST
Research and Markets (http://www.researchandmarkets.com/research/6h349d/orthomyxoviridae) has announced the addition of the Orthomyxoviridae Infections Global Clinical Trials Review, H2, 2014 report to their offering. Orthomyxoviridae Infections Global Clinical Trials Review, H2, 2014 Summary Our clinical trial report, Orthomyxoviridae Infections Global Clinical Trials Review, H2, 2014" provides data on the Orthomyxoviridae Infections clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Orthomyxoviridae Infections. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Orthomyxoviridae Infections. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Our team of industry experts. Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Reasons to buy - Understand the dynamics of a particular indication in a condensed manner - Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more - Obtain discontinued trial listing for trials across the globe - Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies Key Topics Covered: List of Tables List of Figures Introduction Orthomyxoviridae Infections Report Guidance Clinical Trials by Region Clinical Trials and Average Enrollment by Country Top Five Countries Contributing to Clinical Trials in Asia-Pacific Top Five Countries Contributing to Clinical Trials in Europe Top Countries Contributing to Clinical Trials in North America Top Five Countries Contributing to Clinical Trials in Middle East and Africa Top Five Countries Contributing to Clinical Trials in Central and South America Clinical Trials by G7 Countries: Proportion of Orthomyxoviridae Infections to Infectious Disease Clinical Trials Clinical Trials by Phase in G7 Countries Clinical Trials in G7 Countries by Trial Status Clinical Trials by E7 Countries: Proportion of Orthomyxoviridae Infections to Infectious Disease Clinical Trials Clinical Trials by Phase in E7 Countries Clinical Trials in E7 Countries by Trial Status Clinical Trials by Phase In Progress Trials by Phase Clinical Trials by Trial Status Clinical Trials by End Point Status Unaccomplished Trials of Orthomyxoviridae Infections Subjects Recruited Over a Period of Time Clinical Trials by Sponsor Type Prominent Sponsors Top Companies Participating in Orthomyxoviridae Infections Therapeutics Clinical Trials Prominent Drugs Clinical Trial Profiles Clinical Trial Overview of Top Companies GlaxoSmithKline plc Clinical Trial Overview of GlaxoSmithKline plc Novartis AG Clinical Trial Overview of Novartis AG Sanofi Clinical Trial Overview of Sanofi AstraZeneca PLC Clinical Trial Overview of AstraZeneca PLC F. Hoffmann-La Roche Ltd. Clinical Trial Overview of F. Hoffmann-La Roche Ltd. CSL Limited Clinical Trial Overview of CSL Limited Pfizer Inc. Clinical Trial Overview of Pfizer Inc. Baxter International Inc. Clinical Trial Overview of Baxter International Inc. Novavax, Inc. Clinical Trial Overview of Novavax, Inc. Johnson & Johnson Clinical Trial Overview of Johnson & Johnson Clinical Trial Overview of Top Institutes / Government The National Institute of Allergy and Infectious Diseases Clinical Trial Overview of The National Institute of Allergy and Infectious Diseases University of Oxford Clinical Trial Overview of University of Oxford The University of Hong Kong Clinical Trial Overview of The University of Hong Kong Centers for Disease Control and Prevention Clinical Trial Overview of Centers for Disease Control and Prevention National Hospital Organization Mie National Hospital Clinical Trial Overview of National Hospital Organization Mie National Hospital PATH Clinical Trial Overview of PATH University Hospitals of Leicester NHS Trust Clinical Trial Overview of University Hospitals of Leicester NHS Trust University of British Columbia Clinical Trial Overview of University of British Columbia University of the Witwatersrand Clinical Trial Overview of University of the Witwatersrand Institut National de la Sante et de la Recherche Medicale Clinical Trial Overview of Institut National de la Sante et de la Recherche Medicale Five Key Clinical Profiles Appendix Abbreviations Definitions Research Methodology Secondary Research About Us Contact Us Disclaimer Source List of Tables Orthomyxoviridae Infections Therapeutics, Global, Clinical Trials by Region, 2014- Orthomyxoviridae Infections Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014- Orthomyxoviridae Infections Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014- Orthomyxoviridae Infections Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2014- Orthomyxoviridae Infections Therapeutics Clinical Trials, Europe, Top Five Countries, 2014- Orthomyxoviridae Infections Therapeutics Clinical Trials, North America, Top Countries, 2014- Orthomyxoviridae Infections Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2014- Orthomyxoviridae Infections Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2014- Proportion of Orthomyxoviridae Infections to Infectious Disease Clinical Trials, G7 Countries (%), 2014- Orthomyxoviridae Infections Therapeutics, G7 Countries, Clinical Trials by Phase, 2014- Orthomyxoviridae Infections Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014- Proportion of Orthomyxoviridae Infections to Infectious Disease Clinical Trials, E7 Countries (%), 2014- Orthomyxoviridae Infections Therapeutics, E7 Countries, Clinical Trials by Phase, 2014- Orthomyxoviridae Infections Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014- Orthomyxoviridae Infections Therapeutics, Global, Clinical Trials by Phase, 2014- Orthomyxoviridae Infections Therapeutics, Global, Clinical Trials In Progress by Phase 2014- Orthomyxoviridae Infections Therapeutics, Global, Clinical Trials by Trial Status, 2014- Orthomyxoviridae Infections Therapeutics Clinical Trials, Global, by End Point Status, 2014- Orthomyxoviridae Infections Therapeutics, Global, Suspended Clinical Trials, 2014- Orthomyxoviridae Infections Therapeutics, Global, Withdrawn Clinical Trials, 2014- Orthomyxoviridae Infections Therapeutics, Global, Terminated Clinical Trials, 2014- Orthomyxoviridae Infections Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 Orthomyxoviridae Infections Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014- Orthomyxoviridae Infections Therapeutics Clinical Trials, Global, Key Sponsors, 2014- Orthomyxoviridae Infections Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014- Orthomyxoviridae Infections Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014- Orthomyxoviridae Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by GlaxoSmithKline plc, 2014- Orthomyxoviridae Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Novartis AG, 2014- Orthomyxoviridae Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Sanofi, 2014- Orthomyxoviridae Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by AstraZeneca PLC, 2014- Orthomyxoviridae Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by F. Hoffmann-La Roche Ltd., 2014- Orthomyxoviridae Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by CSL Limited, 2014- Orthomyxoviridae Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Pfizer Inc., 2014- Orthomyxoviridae Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Baxter International Inc., 2014- Orthomyxoviridae Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Novavax, Inc., 2014- Orthomyxoviridae Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Johnson & Johnson, 2014- Orthomyxoviridae Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by The National Institute of Allergy and Infectious Diseases, 2014- Orthomyxoviridae Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Oxford, 2014- Orthomyxoviridae Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by The University of Hong Kong, 2014- Orthomyxoviridae Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Centers for Disease Control and Prevention, 2014- Orthomyxoviridae Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by National Hospital Organization Mie National Hospital, 2014- Orthomyxoviridae Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by PATH, 2014- Orthomyxoviridae Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by University Hospitals of Leicester NHS Trust, 2014- Orthomyxoviridae Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by University of British Columbia, 2014- Orthomyxoviridae Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by University of the Witwatersrand, 2014- Orthomyxoviridae Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Institut National de la Sante et de la Recherche Medicale, 2014- List of Figures Orthomyxoviridae Infections Therapeutics, Global, Clinical Trials by Region (%), 2014- Orthomyxoviridae Infections Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014- Orthomyxoviridae Infections Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014- Orthomyxoviridae Infections Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2014- Orthomyxoviridae Infections Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014- Orthomyxoviridae Infections Therapeutics Clinical Trials, North America, Top Countries (%), 2014- Orthomyxoviridae Infections Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2014- Orthomyxoviridae Infections Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2014- Proportion of Orthomyxoviridae Infections to Infectious Disease Clinical Trials, G7 Countries (%), 2014- Orthomyxoviridae Infections Therapeutics, G7 Countries, Clinical Trials by Phase, 2014- Orthomyxoviridae Infections Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014- Proportion of Orthomyxoviridae Infections to Infectious Disease Clinical Trials, E7 Countries (%), 2014- Orthomyxoviridae Infections Therapeutics, E7 Countries, Clinical Trials by Phase, 2014- Orthomyxoviridae Infections Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014- Orthomyxoviridae Infections Therapeutics, Global, Clinical Trials by Phase (%), 2014- Orthomyxoviridae Infections Therapeutics, Global, Clinical Trials In Progress by Phase, 2014- Orthomyxoviridae Infections Therapeutics, Global, Clinical Trials by Trial Status, 2014- Orthomyxoviridae Infections Therapeutics Clinical Trials, Global, by End Point Status, 2014- Orthomyxoviridae Infections Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 Orthomyxoviridae Infections Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014- Orthomyxoviridae Infections Therapeutics Clinical Trials, Global, Key Sponsors, 2014- Orthomyxoviridae Infections Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014- Orthomyxoviridae Infections Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014- GlobalData Methodology For more information visit http://www.researchandmarkets.com/research/6h...yxoviridae About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
JNJ: 125.23 (+0.77), NVAX: 7.32 (-0.06), BAX: 48.02 (-0.20), PFE: 36.89 (+0.22), AZN: 34.14 (-0.15), GSK: 45.07 (-0.11), NVS: 83.26 (+1.18)
Disseminated Intravascular Coagulation (DIC) Global Clinical Trials Review, H2, 2015 - Analysis, Technologies & Forecasts
M2 - Wed Dec 23, 3:51AM CST
Research and Markets (http://www.researchandmarkets.com/research/2gc7w5/disseminated) has announced the addition of the "Disseminated Intravascular Coagulation (DIC) Global Clinical Trials Review, H2, 2015" report to their offering. The clinical trial report, Disseminated Intravascular Coagulation (DIC) Global Clinical Trials Review, H2, 2015" provides an overview of Disseminated Intravascular Coagulation (DIC) clinical trials scenario. This report provides top line data relating to the clinical trials on Disseminated Intravascular Coagulation (DIC). It includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. the eport also provides prominent drugs for in-progress trials (based on number of ongoing trials). Key Topics Covered: - The report provides a snapshot of the global clinical trials landscape - Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status - The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company - The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment - The Report provides enrollment trends for the past five years - Report provides latest news for the past three months Benefits of this Report: - Assists in formulating key business strategies with regards to investment - Helps in identifying prominent locations for conducting clinical trials which saves time and cost - Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities - Supports understanding of trials count and enrollment trends by country in global therapeutics market - Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials - Facilitates clinical trial assessment of the indication on a global, regional and country level Companies Mentioned: - Asahi Kasei Corporation - Kirin Holdings Company, Limited - The LEO Foundation - CSL Limited For more information visit http://www.researchandmarkets.com/research/2g...sseminated
CSL CEO Says Corporate Responsibility And Sustainability Are All About Continuous Improvement
PR Newswire - Fri Dec 18, 7:30AM CST
CSL Limited (ASX:CSL) has recorded another strong performance in corporate responsibility, delivering on its promise to responsibly achieve growth through the disciplined execution of its business strategy, investing in research and development to advance therapies for unmet medical needs, growing its core portfolio of products by expanding indications and markets, and through its commitment to productivity and efficiency.
CSL: 103.29 (-0.67)
Hemophilia B Therapeutics Pipeline Report H2 2015 - 19 Companies & 27 Drug Profiles
M2 - Tue Dec 15, 4:13AM CST
Research and Markets (http://www.researchandmarkets.com/research/2f4z4g/hemophilia_b) has announced the addition of the "Hemophilia B - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Hemophilia B, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hemophilia B and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Alnylam Pharmaceuticals, Inc. - Amarna Therapeutics B.V. - AstraZeneca Plc - Baxalta Incorporated - Bayer AG - Biogen, Inc. - Catalyst Biosciences, Inc. - CSL Limited - Dimension Therapeutics, Inc. - Emergent BioSolutions Inc. - Novo Nordisk A/S - OPKO Health, Inc. - Pfizer Inc. - Pharming Group N.V. - RegenxBio Inc. - rEVO Biologics, Inc. - Sangamo BioSciences, Inc. - Spark Therapeutics, Inc. - uniQure N.V. Drug Profiles - albutrepenonacog alfa - ALN-AT3 - AMT-060 - AZ-10047130 - BAX-335 - BAY-1093884 - CB-2679d - CB-813d - Cell Therapy for Hemophilia B - coagulation factor IX (recombinant) - coagulation factor IX-Fc (recombinant), Fc fusion protein - coagulation factor VIIa (recombinant) - concizumab - CSL-689 - DTX-101 - Gene Therapy for Hemophilia B - Gene Therapy to Activate Factor IX for Hemophilia B - Gene Therapy to Activate Factor IX for Hemophilia B - LR-769 - MOD-5014 - MOD-9017 - nonacog beta pegol - PF-06741086 - SB-FIX - SPK-FIX - SVF-VIIa For more information visit http://www.researchandmarkets.com/research/2f...mophilia_b
EBS: 33.39 (+0.54), PFE: 36.89 (+0.22), SGMO: 6.33 (+0.17), RBIO: (), DMTX: 7.12 (-0.14), NVO: 56.97 (+0.43), OPK: 9.95 (+0.06), ONCE: 57.94 (+2.55), AZN: 34.14 (-0.15), CBIO: 1.49 (unch), BXLT: 46.02 (-0.18)
Kidney Transplantation Therapeutics Pipeline Report 2015 - 25 Companies & 30 Drug Profiles
M2 - Mon Dec 14, 8:27AM CST
Research and Markets (http://www.researchandmarkets.com/research/cqgdxr/kidney) has announced the addition of the "Kidney Transplantation - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Kidney transplantation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Kidney transplantation and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Alexion Pharmaceuticals, Inc. - Amyndas Pharmaceuticals LLC - Angion Biomedica Corp. - Astellas Pharma Inc. - Bio-inRen - Catalyst Biosciences, Inc. - CSL Limited - Digna Biotech, S.L. - Dompe Farmaceutici S.p.A. - Effimune SAS - GlaxoSmithKline Plc - Grifols, S.A. - Hansa Medical AB - Kyowa Hakko Kirin Co., Ltd. - Mabtech Limited - Novartis AG - Onyx Pharmaceuticals, Inc. - Opsona Therapeutics Limited - Pharming Group N.V. - Prolong Pharmaceuticals - Quark Pharmaceuticals, Inc. - Shire Plc - t-cell Europe GmbH - Tiziana Life Sciences Plc - Zyrnat Biotherapeutics SL Drug Profiles - albumin (human) - AMY-101 - AS-2521780 - basiliximab biobetter - BB-3 - belimumab - bleselumab - BRN-1889 - C1 esterase inhibitor (human) - Cardiotrophin-1 - carfilzomib - CB-2782 - Cell Therapy for Kidney Transplantation - CFZ-533 - Dendritic Cell Therapy for Multiple Sclerosis and Kidney Transplantation - eculizumab - EFFI-7H - ETR-002 - FCR-001 - foralumab - FR-104 - FX-06 - Monoclonal Antibody to Inhibit CD47 for Kidney Transplantation, Cardiovascular Disease and Oncology - OPN-305 - QPI-1002 - Recombinant Enzyme to Inhibit Immunoglobulin G for Kidney Transplantation - reparixin - Sanguinate - T-Cell Therapy for Kidney Transplant - ZY-11 For more information visit http://www.researchandmarkets.com/research/cqgdxr/kidney
SHPG: 194.12 (+2.69), CBIO: 1.49 (unch), ALXN: 128.60 (-1.80), GSK: 45.07 (-0.11), NVS: 83.26 (+1.18)
Global H3N2 Infection Therapeutics Pipeline Review 2015 -12 Companies & 23 Drug Profiles
M2 - Thu Dec 03, 7:53AM CST
Research and Markets (http://www.researchandmarkets.com/research/smww8r/h3n2_infection) has announced the addition of the "H3N2 Infection - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for H3N2 Infection, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for H3N2 Infection and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Aphios Corporation - Crucell N.V. - CSL Limited - ILiAD Biotechnologies, LLC - Inovio Pharmaceuticals, Inc. - Johnson & Johnson - Medicago Inc. - Mucosis B.V. - NanoViricides, Inc. - REPLICor Inc. - Sarepta Therapeutics, Inc. - Takeda Pharmaceutical Company Limited Drug Profiles - APP-0205 - APP-309 - Aspidasept - C-05 - CR-9114 - Gamma-Flu - ID-38 - influenza [strain A/H3N2] (monovalent) vaccine - influenza [strain A/H3N2] vaccine - influenza [strains A/H1N1 A/H3N2 B] (trivalent) vaccine - influenza [strains A/H1N1 A/H3N2 B] (trivalent) vaccine - influenza [strains A/H1N1 A/H3N2 B] (trivalent, split virion) vaccine - influenza [Strains H1N1, H3N2, influenza B] (quadrivalent) virus like particle vaccine - influenza vaccine - JNJ-872 - Monoclonal Antibody for Influenza A Infections - NVINF-1 - NVINF-2 - pertussis [strain BPZE1] vaccine - PNSIA-28 - radavirsen - REP-9 - Small Molecules for RSV and Influenza A Infections For more information visit http://www.researchandmarkets.com/research/sm..._infection
JNJ: 125.23 (+0.77), INO: 9.88 (+0.26), SRPT: 25.28 (+0.62), NNVC: 1.75 (-0.02)
Global Allergic Asthma Pipeline Review, H2 2015
M2 - Mon Nov 09, 9:33AM CST
Research and Markets (http://www.researchandmarkets.com/research/68lwk7/allergic_asthma) has announced the addition of the "Allergic Asthma - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Allergic Asthma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Allergic Asthma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned - ALK-Abello A/S - Allergopharma Joachim Ganzer KG - Array BioPharma Inc. - Aslan Pharmaceuticals Pte. Ltd. - BioTech Tools s.a. - CSL Limited - Fountain Biopharma Inc. - GlaxoSmithKline Plc - Infinity Pharmaceuticals, Inc. - Kineta, Inc. - Mabtech AB - Marinomed Biotechnologie GmbH - NeoPharm Co., Ltd. - Novartis AG - Nuvo Research Inc. - Oxagen Limited - Panacea Biotec Limited - Peptinnovate Limited - Pharmaxis Limited - Portola Pharmaceuticals, Inc. - Protectimmun GmbH - Pulmatrix, Inc. - Stallergenes S.A. - sterna biologicals Gmbh & Co KG - Swecure AB - The International Biotechnology Center (IBC) Generium - Verona Pharma Plc For more information visit http://www.researchandmarkets.com/research/68...gic_asthma
PTLA: 25.96 (+0.04), GSK: 45.07 (-0.11), PULM: 2.12 (-0.05), INFI: 1.68 (+0.06), ARRY: 3.74 (-0.03), NVS: 83.26 (+1.18)
Systemic Sclerosis (Scleroderma) Pipeline Review, H2 2015 - 24 Companies & 35 Drug Profiles
M2 - Fri Nov 06, 8:21AM CST
Research and Markets (http://www.researchandmarkets.com/research/v8xzj6/systemic) has announced the addition of the "Systemic Sclerosis (Scleroderma) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Systemic Sclerosis (Scleroderma), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Systemic Sclerosis (Scleroderma) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Allergan Plc - Angion Biomedica Corp. - arGentis Pharmaceuticals, LLC - Bayer AG - BioLineRx, Ltd. - BiOrion Technologies B.V. - Bristol-Myers Squibb Company - Celgene Corporation - Corbus pharmaceuticals, Inc. - CSL Limited - Daval International Limited - Digna Biotech, S.L. - F. Hoffmann-La Roche Ltd. - Fibrocell Science, Inc. - GlaxoSmithKline Plc - iBio, Inc. - Inventiva SAS - Kadmon Corporation, LLC - MedImmune, LLC - NovaLead Pharma Pvt. Ltd. - Peptinov SAS - Stratatech Corporation - Vida Therapeutics Inc. - VivaCell Biotechnology Espana S.L. Drug Profiles - abatacept - acALY-18 - Aimspro - ANG-3070 - ARG-201 - belimumab - BL-1110 - BOT-191 - C-82 - CC-220 - disitertide - factor XIII (human) - FCX-013 - GSK-2330811 - IBIOCFB-03 - inebilizumab - IVA-337 - JBT-101 - KD-025 - NLP-491 - Oligonucleotide for Scleroderma - onabotulinumtoxin A - P-17 - PAT-048 - PDX-002 - PPV-06 - riociguat - Small Molecule to Inhibit NFkB for Immunology and Oncology - Stem Cell Therapy for Crohns Disease, Systemic Sclerosis and Multiple Sclerosis - StrataGraft Skin Tissue - Synthetic Peptides to Inhibit TCR for Autoimmune Disorders and Dermatitis - tocilizumab - VCE-0048 - VEDA-1209 - VTI-1000 Series For more information visit http://www.researchandmarkets.com/research/v8xzj6/systemic
AGN: 252.95 (-2.61), FCSC: 1.09 (unch), IBIO: 0.61 (-0.02), GSK: 45.07 (-0.11), BMY: 74.81 (+0.15), CELGZ: 1.16 (-0.01)
NVS Influenza Vaccines Welcomes North Carolina Congresswoman Renee Ellmers on Tour of Holly Springs Manufacturing Facility
PR Newswire - Tue Oct 13, 8:38AM CDT
Yesterday Congresswoman Renee Ellmers (R-NC-02) visited the award-winning NVS Influenza Vaccines Holly Springs manufacturing site located in Holly Springs, NC.4 Since 2014, the facility has produced Flucelvax® (Influenza Vaccine) using cell-culture technology, a state-of-the-art production method that has the potential for faster start-up and is not reliant on chicken eggs.1,2 On July 31, 2015 CSL Limited acquired the influenza vaccines business of Novartis AG in the US, which for an interim period is referred to as NVS Influenza Vaccines.1
CSL: 103.29 (-0.67), NVS: 83.26 (+1.18)
Xencor's Partner begins Phase 2 clinical trial of biologic candidate using XmAb Cytotoxic Fc Domain
M2 - Fri Sep 25, 3:01AM CDT
Biopharmaceutical company Xencor (NasdaqGM:XNCR) disclosed on Thursday that it has begun a Phase 2 clinical trial for CSL362 (JNJ-56022473) using its XmAb Cytotoxic Fc Domain technology.
XNCR: 18.94 (+0.38)
FDA Advisory Panel Recommends Licensure of NVS Influenza Candidate Vaccine for Protection Against Seasonal Influenza in the Elderly
PR Newswire - Tue Sep 15, 12:40PM CDT
NVS Influenza Vaccines, now owned and operated by the CSL Limited, announced today that the Vaccines and Related Biological Products Advisory Committee (VRBPAC) of the US Food and Drug Administration (FDA) voted to recommend licensure of a candidate vaccine to help protect against seasonal influenza in those aged 65 years and older via accelerated approval. Currently under review by the FDA and if approved, the candidate vaccine would become the first adjuvanted seasonal influenza vaccine licensed for use in adults aged 65 and older in the US.1
NVS: 83.26 (+1.18)
Seqirus Commemorates 100 Years of Parent Company, CSL, Delivering on its Promise to Develop Innovative Therapies
PR Newswire Europe - Mon Apr 25, 7:01AM CDT
Seqirus today commemorated with parent company, CSL Limited, 100 years of developing and delivering innovative therapies, including influenza vaccines and treatments that protect and save lives of people with serious and chronic medical conditions. To mark this milestone, CSL announced a A$25 million R&D Fellowship program for early stage and translational research.
Neutropenia Pipeline Market Reviewed for H2 2015
PR Newswire - Thu Mar 10, 8:00PM CST
The "Neutropenia - Pipeline Review, H2 2015" market research report provides an overview of the Neutropenia's therapeutic pipeline. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
CHRS: 25.39 (+0.82)
Haemophilus influenzae Type B Infections Pipeline Review, H2 2015
M2 - Thu Jan 28, 3:50AM CST
Research and Markets (http://www.researchandmarkets.com/research/x4kxq2/haemophilus) has announced the addition of the "Haemophilus influenzae Type B Infections - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Haemophilus influenzae Type B Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Haemophilus influenzae Type B Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Haemophilus influenzae Type B Infections Overview - Therapeutics Development - Pipeline Products for Haemophilus influenzae Type B Infections - Overview - Pipeline Products for Haemophilus influenzae Type B Infections - Comparative Analysis - Haemophilus influenzae Type B Infections - Therapeutics under Development by Companies - Haemophilus influenzae Type B Infections - Therapeutics under Investigation by Universities/Institutes - Haemophilus influenzae Type B Infections - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Haemophilus influenzae Type B Infections - Products under Development by Companies - Haemophilus influenzae Type B Infections - Products under Investigation by Universities/Institutes - Haemophilus influenzae Type B Infections - Companies Involved in Therapeutics Development - Beijing Minhai Biotechnology Co., Ltd - Biological E. Limited - CSL Limited - Daiichi Sankyo Company, Limited - Indian Immunologicals Limited - LG Life Science LTD. - Nuron Biotech, Inc. - Panacea Biotec Limited - Sanofi Pasteur SA - Sinovac Biotech Ltd. - Zydus Cadila Healthcare Limited For more information visit http://www.researchandmarkets.com/research/x4...aemophilus
SVA: 5.90 (+0.05)
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline Review, H2 2015
M2 - Wed Jan 27, 8:33AM CST
Research and Markets (http://www.researchandmarkets.com/research/hfx77x/hereditary) has announced the addition of the "Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Overview - Therapeutics Development - Pipeline Products for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Overview - Pipeline Products for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Comparative Analysis - Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Therapeutics under Development by Companies - Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Therapeutics under Investigation by Universities/Institutes - Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Products under Development by Companies - Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Products under Investigation by Universities/Institutes - Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Companies Involved in Therapeutics Development - Arrowhead Research Corporation - BioCryst Pharmaceuticals, Inc. - Cevec Pharmaceuticals GmbH - CSL Limited - Dyax Corp. - Global Blood Therapeutics, Inc. - iBio, Inc. - Isis Pharmaceuticals, Inc. - Pharming Group N.V. - ProMetic Life Sciences Inc. - Ra Pharmaceuticals, Inc. - Shire Plc For more information visit http://www.researchandmarkets.com/research/hfx77x/hereditary
GBT: 17.88 (+0.27), BCRX: 3.62 (+0.16), ISIS: 57.56 (-0.28), ARWR: 5.96 (-0.02), SHPG: 194.12 (+2.69), IBIO: 0.61 (-0.02), DYAX: 38.04 (-0.37)
Hemophilia A Therapeutics Pipeline Review 2015
M2 - Fri Jan 22, 6:00AM CST
Research and Markets (http://www.researchandmarkets.com/research/5rtzx4/hemophilia_a) has announced the addition of the "Hemophilia A - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Hemophilia A, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hemophilia A and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Hemophilia A Overview - Therapeutics Development - Pipeline Products for Hemophilia A - Overview - Pipeline Products for Hemophilia A - Comparative Analysis - Hemophilia A - Therapeutics under Development by Companies - Hemophilia A - Therapeutics under Investigation by Universities/Institutes - Hemophilia A - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Hemophilia A - Products under Development by Companies - Hemophilia A - Products under Investigation by Universities/Institutes - Hemophilia A - Companies Involved in Therapeutics Development - Alnylam Pharmaceuticals, Inc. - Amarna Therapeutics B.V. - Apitope International NV - AstraZeneca Plc - Baxalta Incorporated - Bayer AG - Biogen, Inc. - BioMarin Pharmaceutical Inc. - Catalyst Biosciences, Inc. - Celtic Pharmaceutical Holdings L.P. - CSL Limited - DBV Technologies S.A. - Dimension Therapeutics, Inc. - Dong-A Socio Group - Emergent BioSolutions Inc. - EpiVax, Inc. - Expression Therapeutics LLC - F. Hoffmann-La Roche Ltd. - Green Cross Corporation - Inbiopro Solutions Pvt. Ltd. - Lentigen Technology, Inc. - mAbxience S.A. - Novo Nordisk A/S - OPKO Health, Inc. - Pfizer Inc. - Pharming Group N.V. - rEVO Biologics, Inc. - Sangamo BioSciences, Inc. - Selecta Biosciences, Inc. - SK Chemicals Co., Ltd. - Spark Therapeutics, Inc. - The International Biotechnology Center (IBC) Generium - uniQure N.V. For more information visit http://www.researchandmarkets.com/research/5r...mophilia_a
BMRN: 99.42 (+1.22), EBS: 33.39 (+0.54), PFE: 36.89 (+0.22), SGMO: 6.33 (+0.17), RBIO: (), DMTX: 7.12 (-0.14), NVO: 56.97 (+0.43), OPK: 9.95 (+0.06), ONCE: 57.94 (+2.55), AZN: 34.14 (-0.15), CBIO: 1.49 (unch), BXLT: 46.02 (-0.18)
Neutropenia Therapeutics Pipeline Review, H2 2015
M2 - Mon Jan 18, 5:43AM CST
Research and Markets (http://www.researchandmarkets.com/research/4ffs34/neutropenia) has announced the addition of the "Neutropenia - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Neutropenia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Neutropenia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Neutropenia Overview - Therapeutics Development - Pipeline Products for Neutropenia - Overview - Pipeline Products for Neutropenia - Comparative Analysis - Neutropenia - Therapeutics under Development by Companies - Neutropenia - Therapeutics under Investigation by Universities/Institutes - Neutropenia - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Neutropenia - Products under Development by Companies - Neutropenia - Products under Investigation by Universities/Institutes - Neutropenia - Companies Involved in Therapeutics Development - Apotex, Inc. - Biocon Limited - Biogenomics Limited - Cellerant Therapeutics, Inc. - Coherus BioSciences, Inc. - CSL Limited - Dr. Reddy's Laboratories Limited - Inbiopro Solutions Pvt. Ltd. - Ligand Pharmaceuticals, Inc. - NAL Pharmaceuticals Ltd. - Prolong Pharmaceuticals - Richter Gedeon Nyrt. - Sandoz International GmbH - Therapeutic Proteins International, LLC - Toko Pharmaceutical Industries Co., Ltd. - USV Limited For more information visit http://www.researchandmarkets.com/research/4f...eutropenia
CHRS: 25.39 (+0.82)
Global Blood Plasma Market Growth of 10.54% CAGR by 2020 - Analysis, Technologies & Forecasts Report 2015-2020
M2 - Mon Jan 18, 5:29AM CST
Research and Markets (http://www.researchandmarkets.com/research/q4rkcg/global_blood) has announced the addition of the "Global Blood Plasma Market: Trends, Opportunities and Forecasts (2015-2020) - (By Market Segment, Type of Blood Plasma -IVIG, Albumin, Factor VIII, By Region-North America, Europe, APAC, Market Entry Strategies for Global Players)" report to their offering. According to this research report the global blood plasma market is projected to exhibit a CAGR of 10.54% during 2015 - 2020. Few of the leading companies operating in blood plasma market in world include CSL Behring, Baxter, Grifols SA and Octapharma, etc. Benefits of this Report: - To gain an in-depth understanding of Global Blood Plasma Market - To identify the on-going trends and anticipated growth in the next five years - To help industry consultants, blood plasma manufacturers, suppliers and distributors align their market-centric strategies - To gain insights on the prevalent market entry strategies in blood plasma market for domestic as well as foreign companies - To obtain research based business decision and add weight to presentations and marketing material Companies Mentioned: - AMAG Pharmaceuticals, Inc. - Antares Pharma Inc - Baxter International Inc - BioDelivery Sciences International, Inc. - Biota Pharmaceuticals, Inc. - CSL Ltd. - Cipla - Emergent BioSolutions, Inc. - Grifols S.A - Octopharma Report Structure: 1. Research Methodology 2. Product Overview 3. Executive Summary 4. Global Blood Plasma Market: An Analysis 5. North America Blood Plasma Market: Size, Growth and Forecast 6. APAC Blood Plasma Market: Size, Growth and Forecast 7. Europe Blood Plasma Market: Size, Growth and Forecast 8. RoW Blood Plasma Market: Size, Growth and Forecast 9. Blood Plasma Market Trends 10. Global Blood Plasma Market Dynamics 11. Blood Plasma Market: Policy and Regulatory Landscape 12. Blood Plasma Market: Value Chain Analysis 13. Blood Plasma Trade Data Analysis 14. Blood Plasma Market: Porter's Five Force Analysis 15. Blood Plasma Market: Competitive landscape 16. Global Blood Plasma Market: Company Profiles 17. Strategic Recommendations For more information visit http://www.researchandmarkets.com/research/q4...obal_blood
BDSI: 2.55 (+0.20), EBS: 33.39 (+0.54), BOTA: 1.55 (-0.04), BAX: 48.02 (-0.20), AMAG: 26.53 (-0.06), ATRS: 1.00 (-0.02)
CSL Limited - Product Pipeline Market Review - 2015: Latest Report By Radiant Insights, Inc
M2 - Mon Jan 11, 4:45AM CST
Radiantinsights.com has include "CSL Limited - Product Pipeline Review - 2015" to their Database.
Diabetic Nephropathy Pipeline Review, H2 2015 - Analysis & Opportunities
M2 - Tue Dec 29, 5:07AM CST
Research and Markets (http://www.researchandmarkets.com/research/4pj8km/diabetic) has announced the addition of the "Diabetic Nephropathy - Pipeline Review, H2 2015" report to their offering. The report Diabetic Nephropathy - Pipeline Review, H2 2015', provides an overview of the Diabetic Nephropathy's therapeutic pipeline. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - The report provides a snapshot of the global therapeutic landscape of Diabetic Nephropathy - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Diabetic Nephropathy and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Diabetic Nephropathy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Benefits of this Report: - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Diabetic Nephropathy - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Diabetic Nephropathy pipeline depth and focus of Indication therapeutics Companies Mentioned Include: - AbbVie Inc. - Aerpio Therapeutics, Inc. - Antisense Therapeutics Limited - Astellas Pharma Inc. - AstraZeneca Plc - Bayer AG - BiOrion Technologies B.V. - Cellmid Limited - ChemoCentryx, Inc. - Concert Pharmaceuticals, Inc. - CSL Limited - GlaxoSmithKline Plc - Glucox Biotech AB - Pfizer Inc. - PhytoHealth Corporation - ProMetic Life Sciences Inc. - Serodus ASA - Shire Plc - Takeda Pharmaceutical Company Limited - Tobira Therapeutics, Inc. - Torrent Pharmaceuticals Limited - Vascular Pharmaceuticals, Inc. - Vicore Pharma AB - XOMA Corporation For more information visit http://www.researchandmarkets.com/research/4pj8km/diabetic
PFE: 36.89 (+0.22), GSK: 45.07 (-0.11), CNCE: 11.49 (-0.28), AZN: 34.14 (-0.15), SHPG: 194.12 (+2.69), CCXI: 4.70 (+0.01), ABBV: 66.23 (+1.51), TBRA: 4.31 (+0.04), XOMA: 0.67 (+0.09)
Orthomyxoviridae Infections Global Clinical Trials Review, H2, 2014
M2 - Wed Dec 23, 6:00AM CST
Research and Markets (http://www.researchandmarkets.com/research/6h349d/orthomyxoviridae) has announced the addition of the Orthomyxoviridae Infections Global Clinical Trials Review, H2, 2014 report to their offering. Orthomyxoviridae Infections Global Clinical Trials Review, H2, 2014 Summary Our clinical trial report, Orthomyxoviridae Infections Global Clinical Trials Review, H2, 2014" provides data on the Orthomyxoviridae Infections clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Orthomyxoviridae Infections. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Orthomyxoviridae Infections. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Our team of industry experts. Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Reasons to buy - Understand the dynamics of a particular indication in a condensed manner - Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more - Obtain discontinued trial listing for trials across the globe - Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies Key Topics Covered: List of Tables List of Figures Introduction Orthomyxoviridae Infections Report Guidance Clinical Trials by Region Clinical Trials and Average Enrollment by Country Top Five Countries Contributing to Clinical Trials in Asia-Pacific Top Five Countries Contributing to Clinical Trials in Europe Top Countries Contributing to Clinical Trials in North America Top Five Countries Contributing to Clinical Trials in Middle East and Africa Top Five Countries Contributing to Clinical Trials in Central and South America Clinical Trials by G7 Countries: Proportion of Orthomyxoviridae Infections to Infectious Disease Clinical Trials Clinical Trials by Phase in G7 Countries Clinical Trials in G7 Countries by Trial Status Clinical Trials by E7 Countries: Proportion of Orthomyxoviridae Infections to Infectious Disease Clinical Trials Clinical Trials by Phase in E7 Countries Clinical Trials in E7 Countries by Trial Status Clinical Trials by Phase In Progress Trials by Phase Clinical Trials by Trial Status Clinical Trials by End Point Status Unaccomplished Trials of Orthomyxoviridae Infections Subjects Recruited Over a Period of Time Clinical Trials by Sponsor Type Prominent Sponsors Top Companies Participating in Orthomyxoviridae Infections Therapeutics Clinical Trials Prominent Drugs Clinical Trial Profiles Clinical Trial Overview of Top Companies GlaxoSmithKline plc Clinical Trial Overview of GlaxoSmithKline plc Novartis AG Clinical Trial Overview of Novartis AG Sanofi Clinical Trial Overview of Sanofi AstraZeneca PLC Clinical Trial Overview of AstraZeneca PLC F. Hoffmann-La Roche Ltd. Clinical Trial Overview of F. Hoffmann-La Roche Ltd. CSL Limited Clinical Trial Overview of CSL Limited Pfizer Inc. Clinical Trial Overview of Pfizer Inc. Baxter International Inc. Clinical Trial Overview of Baxter International Inc. Novavax, Inc. Clinical Trial Overview of Novavax, Inc. Johnson & Johnson Clinical Trial Overview of Johnson & Johnson Clinical Trial Overview of Top Institutes / Government The National Institute of Allergy and Infectious Diseases Clinical Trial Overview of The National Institute of Allergy and Infectious Diseases University of Oxford Clinical Trial Overview of University of Oxford The University of Hong Kong Clinical Trial Overview of The University of Hong Kong Centers for Disease Control and Prevention Clinical Trial Overview of Centers for Disease Control and Prevention National Hospital Organization Mie National Hospital Clinical Trial Overview of National Hospital Organization Mie National Hospital PATH Clinical Trial Overview of PATH University Hospitals of Leicester NHS Trust Clinical Trial Overview of University Hospitals of Leicester NHS Trust University of British Columbia Clinical Trial Overview of University of British Columbia University of the Witwatersrand Clinical Trial Overview of University of the Witwatersrand Institut National de la Sante et de la Recherche Medicale Clinical Trial Overview of Institut National de la Sante et de la Recherche Medicale Five Key Clinical Profiles Appendix Abbreviations Definitions Research Methodology Secondary Research About Us Contact Us Disclaimer Source List of Tables Orthomyxoviridae Infections Therapeutics, Global, Clinical Trials by Region, 2014- Orthomyxoviridae Infections Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014- Orthomyxoviridae Infections Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014- Orthomyxoviridae Infections Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2014- Orthomyxoviridae Infections Therapeutics Clinical Trials, Europe, Top Five Countries, 2014- Orthomyxoviridae Infections Therapeutics Clinical Trials, North America, Top Countries, 2014- Orthomyxoviridae Infections Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2014- Orthomyxoviridae Infections Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2014- Proportion of Orthomyxoviridae Infections to Infectious Disease Clinical Trials, G7 Countries (%), 2014- Orthomyxoviridae Infections Therapeutics, G7 Countries, Clinical Trials by Phase, 2014- Orthomyxoviridae Infections Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014- Proportion of Orthomyxoviridae Infections to Infectious Disease Clinical Trials, E7 Countries (%), 2014- Orthomyxoviridae Infections Therapeutics, E7 Countries, Clinical Trials by Phase, 2014- Orthomyxoviridae Infections Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014- Orthomyxoviridae Infections Therapeutics, Global, Clinical Trials by Phase, 2014- Orthomyxoviridae Infections Therapeutics, Global, Clinical Trials In Progress by Phase 2014- Orthomyxoviridae Infections Therapeutics, Global, Clinical Trials by Trial Status, 2014- Orthomyxoviridae Infections Therapeutics Clinical Trials, Global, by End Point Status, 2014- Orthomyxoviridae Infections Therapeutics, Global, Suspended Clinical Trials, 2014- Orthomyxoviridae Infections Therapeutics, Global, Withdrawn Clinical Trials, 2014- Orthomyxoviridae Infections Therapeutics, Global, Terminated Clinical Trials, 2014- Orthomyxoviridae Infections Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 Orthomyxoviridae Infections Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014- Orthomyxoviridae Infections Therapeutics Clinical Trials, Global, Key Sponsors, 2014- Orthomyxoviridae Infections Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014- Orthomyxoviridae Infections Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014- Orthomyxoviridae Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by GlaxoSmithKline plc, 2014- Orthomyxoviridae Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Novartis AG, 2014- Orthomyxoviridae Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Sanofi, 2014- Orthomyxoviridae Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by AstraZeneca PLC, 2014- Orthomyxoviridae Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by F. Hoffmann-La Roche Ltd., 2014- Orthomyxoviridae Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by CSL Limited, 2014- Orthomyxoviridae Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Pfizer Inc., 2014- Orthomyxoviridae Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Baxter International Inc., 2014- Orthomyxoviridae Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Novavax, Inc., 2014- Orthomyxoviridae Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Johnson & Johnson, 2014- Orthomyxoviridae Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by The National Institute of Allergy and Infectious Diseases, 2014- Orthomyxoviridae Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Oxford, 2014- Orthomyxoviridae Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by The University of Hong Kong, 2014- Orthomyxoviridae Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Centers for Disease Control and Prevention, 2014- Orthomyxoviridae Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by National Hospital Organization Mie National Hospital, 2014- Orthomyxoviridae Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by PATH, 2014- Orthomyxoviridae Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by University Hospitals of Leicester NHS Trust, 2014- Orthomyxoviridae Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by University of British Columbia, 2014- Orthomyxoviridae Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by University of the Witwatersrand, 2014- Orthomyxoviridae Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Institut National de la Sante et de la Recherche Medicale, 2014- List of Figures Orthomyxoviridae Infections Therapeutics, Global, Clinical Trials by Region (%), 2014- Orthomyxoviridae Infections Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014- Orthomyxoviridae Infections Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014- Orthomyxoviridae Infections Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2014- Orthomyxoviridae Infections Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014- Orthomyxoviridae Infections Therapeutics Clinical Trials, North America, Top Countries (%), 2014- Orthomyxoviridae Infections Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2014- Orthomyxoviridae Infections Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2014- Proportion of Orthomyxoviridae Infections to Infectious Disease Clinical Trials, G7 Countries (%), 2014- Orthomyxoviridae Infections Therapeutics, G7 Countries, Clinical Trials by Phase, 2014- Orthomyxoviridae Infections Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014- Proportion of Orthomyxoviridae Infections to Infectious Disease Clinical Trials, E7 Countries (%), 2014- Orthomyxoviridae Infections Therapeutics, E7 Countries, Clinical Trials by Phase, 2014- Orthomyxoviridae Infections Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014- Orthomyxoviridae Infections Therapeutics, Global, Clinical Trials by Phase (%), 2014- Orthomyxoviridae Infections Therapeutics, Global, Clinical Trials In Progress by Phase, 2014- Orthomyxoviridae Infections Therapeutics, Global, Clinical Trials by Trial Status, 2014- Orthomyxoviridae Infections Therapeutics Clinical Trials, Global, by End Point Status, 2014- Orthomyxoviridae Infections Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 Orthomyxoviridae Infections Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014- Orthomyxoviridae Infections Therapeutics Clinical Trials, Global, Key Sponsors, 2014- Orthomyxoviridae Infections Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014- Orthomyxoviridae Infections Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014- GlobalData Methodology For more information visit http://www.researchandmarkets.com/research/6h...yxoviridae About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
JNJ: 125.23 (+0.77), NVAX: 7.32 (-0.06), BAX: 48.02 (-0.20), PFE: 36.89 (+0.22), AZN: 34.14 (-0.15), GSK: 45.07 (-0.11), NVS: 83.26 (+1.18)
Disseminated Intravascular Coagulation (DIC) Global Clinical Trials Review, H2, 2015 - Analysis, Technologies & Forecasts
M2 - Wed Dec 23, 3:51AM CST
Research and Markets (http://www.researchandmarkets.com/research/2gc7w5/disseminated) has announced the addition of the "Disseminated Intravascular Coagulation (DIC) Global Clinical Trials Review, H2, 2015" report to their offering. The clinical trial report, Disseminated Intravascular Coagulation (DIC) Global Clinical Trials Review, H2, 2015" provides an overview of Disseminated Intravascular Coagulation (DIC) clinical trials scenario. This report provides top line data relating to the clinical trials on Disseminated Intravascular Coagulation (DIC). It includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. the eport also provides prominent drugs for in-progress trials (based on number of ongoing trials). Key Topics Covered: - The report provides a snapshot of the global clinical trials landscape - Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status - The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company - The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment - The Report provides enrollment trends for the past five years - Report provides latest news for the past three months Benefits of this Report: - Assists in formulating key business strategies with regards to investment - Helps in identifying prominent locations for conducting clinical trials which saves time and cost - Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities - Supports understanding of trials count and enrollment trends by country in global therapeutics market - Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials - Facilitates clinical trial assessment of the indication on a global, regional and country level Companies Mentioned: - Asahi Kasei Corporation - Kirin Holdings Company, Limited - The LEO Foundation - CSL Limited For more information visit http://www.researchandmarkets.com/research/2g...sseminated
CSL CEO Says Corporate Responsibility And Sustainability Are All About Continuous Improvement
PR Newswire - Fri Dec 18, 7:30AM CST
CSL Limited (ASX:CSL) has recorded another strong performance in corporate responsibility, delivering on its promise to responsibly achieve growth through the disciplined execution of its business strategy, investing in research and development to advance therapies for unmet medical needs, growing its core portfolio of products by expanding indications and markets, and through its commitment to productivity and efficiency.
CSL: 103.29 (-0.67)
Hemophilia B Therapeutics Pipeline Report H2 2015 - 19 Companies & 27 Drug Profiles
M2 - Tue Dec 15, 4:13AM CST
Research and Markets (http://www.researchandmarkets.com/research/2f4z4g/hemophilia_b) has announced the addition of the "Hemophilia B - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Hemophilia B, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hemophilia B and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Alnylam Pharmaceuticals, Inc. - Amarna Therapeutics B.V. - AstraZeneca Plc - Baxalta Incorporated - Bayer AG - Biogen, Inc. - Catalyst Biosciences, Inc. - CSL Limited - Dimension Therapeutics, Inc. - Emergent BioSolutions Inc. - Novo Nordisk A/S - OPKO Health, Inc. - Pfizer Inc. - Pharming Group N.V. - RegenxBio Inc. - rEVO Biologics, Inc. - Sangamo BioSciences, Inc. - Spark Therapeutics, Inc. - uniQure N.V. Drug Profiles - albutrepenonacog alfa - ALN-AT3 - AMT-060 - AZ-10047130 - BAX-335 - BAY-1093884 - CB-2679d - CB-813d - Cell Therapy for Hemophilia B - coagulation factor IX (recombinant) - coagulation factor IX-Fc (recombinant), Fc fusion protein - coagulation factor VIIa (recombinant) - concizumab - CSL-689 - DTX-101 - Gene Therapy for Hemophilia B - Gene Therapy to Activate Factor IX for Hemophilia B - Gene Therapy to Activate Factor IX for Hemophilia B - LR-769 - MOD-5014 - MOD-9017 - nonacog beta pegol - PF-06741086 - SB-FIX - SPK-FIX - SVF-VIIa For more information visit http://www.researchandmarkets.com/research/2f...mophilia_b
EBS: 33.39 (+0.54), PFE: 36.89 (+0.22), SGMO: 6.33 (+0.17), RBIO: (), DMTX: 7.12 (-0.14), NVO: 56.97 (+0.43), OPK: 9.95 (+0.06), ONCE: 57.94 (+2.55), AZN: 34.14 (-0.15), CBIO: 1.49 (unch), BXLT: 46.02 (-0.18)
Kidney Transplantation Therapeutics Pipeline Report 2015 - 25 Companies & 30 Drug Profiles
M2 - Mon Dec 14, 8:27AM CST
Research and Markets (http://www.researchandmarkets.com/research/cqgdxr/kidney) has announced the addition of the "Kidney Transplantation - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Kidney transplantation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Kidney transplantation and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Alexion Pharmaceuticals, Inc. - Amyndas Pharmaceuticals LLC - Angion Biomedica Corp. - Astellas Pharma Inc. - Bio-inRen - Catalyst Biosciences, Inc. - CSL Limited - Digna Biotech, S.L. - Dompe Farmaceutici S.p.A. - Effimune SAS - GlaxoSmithKline Plc - Grifols, S.A. - Hansa Medical AB - Kyowa Hakko Kirin Co., Ltd. - Mabtech Limited - Novartis AG - Onyx Pharmaceuticals, Inc. - Opsona Therapeutics Limited - Pharming Group N.V. - Prolong Pharmaceuticals - Quark Pharmaceuticals, Inc. - Shire Plc - t-cell Europe GmbH - Tiziana Life Sciences Plc - Zyrnat Biotherapeutics SL Drug Profiles - albumin (human) - AMY-101 - AS-2521780 - basiliximab biobetter - BB-3 - belimumab - bleselumab - BRN-1889 - C1 esterase inhibitor (human) - Cardiotrophin-1 - carfilzomib - CB-2782 - Cell Therapy for Kidney Transplantation - CFZ-533 - Dendritic Cell Therapy for Multiple Sclerosis and Kidney Transplantation - eculizumab - EFFI-7H - ETR-002 - FCR-001 - foralumab - FR-104 - FX-06 - Monoclonal Antibody to Inhibit CD47 for Kidney Transplantation, Cardiovascular Disease and Oncology - OPN-305 - QPI-1002 - Recombinant Enzyme to Inhibit Immunoglobulin G for Kidney Transplantation - reparixin - Sanguinate - T-Cell Therapy for Kidney Transplant - ZY-11 For more information visit http://www.researchandmarkets.com/research/cqgdxr/kidney
SHPG: 194.12 (+2.69), CBIO: 1.49 (unch), ALXN: 128.60 (-1.80), GSK: 45.07 (-0.11), NVS: 83.26 (+1.18)
Global H3N2 Infection Therapeutics Pipeline Review 2015 -12 Companies & 23 Drug Profiles
M2 - Thu Dec 03, 7:53AM CST
Research and Markets (http://www.researchandmarkets.com/research/smww8r/h3n2_infection) has announced the addition of the "H3N2 Infection - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for H3N2 Infection, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for H3N2 Infection and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Aphios Corporation - Crucell N.V. - CSL Limited - ILiAD Biotechnologies, LLC - Inovio Pharmaceuticals, Inc. - Johnson & Johnson - Medicago Inc. - Mucosis B.V. - NanoViricides, Inc. - REPLICor Inc. - Sarepta Therapeutics, Inc. - Takeda Pharmaceutical Company Limited Drug Profiles - APP-0205 - APP-309 - Aspidasept - C-05 - CR-9114 - Gamma-Flu - ID-38 - influenza [strain A/H3N2] (monovalent) vaccine - influenza [strain A/H3N2] vaccine - influenza [strains A/H1N1 A/H3N2 B] (trivalent) vaccine - influenza [strains A/H1N1 A/H3N2 B] (trivalent) vaccine - influenza [strains A/H1N1 A/H3N2 B] (trivalent, split virion) vaccine - influenza [Strains H1N1, H3N2, influenza B] (quadrivalent) virus like particle vaccine - influenza vaccine - JNJ-872 - Monoclonal Antibody for Influenza A Infections - NVINF-1 - NVINF-2 - pertussis [strain BPZE1] vaccine - PNSIA-28 - radavirsen - REP-9 - Small Molecules for RSV and Influenza A Infections For more information visit http://www.researchandmarkets.com/research/sm..._infection
JNJ: 125.23 (+0.77), INO: 9.88 (+0.26), SRPT: 25.28 (+0.62), NNVC: 1.75 (-0.02)
Global Allergic Asthma Pipeline Review, H2 2015
M2 - Mon Nov 09, 9:33AM CST
Research and Markets (http://www.researchandmarkets.com/research/68lwk7/allergic_asthma) has announced the addition of the "Allergic Asthma - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Allergic Asthma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Allergic Asthma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned - ALK-Abello A/S - Allergopharma Joachim Ganzer KG - Array BioPharma Inc. - Aslan Pharmaceuticals Pte. Ltd. - BioTech Tools s.a. - CSL Limited - Fountain Biopharma Inc. - GlaxoSmithKline Plc - Infinity Pharmaceuticals, Inc. - Kineta, Inc. - Mabtech AB - Marinomed Biotechnologie GmbH - NeoPharm Co., Ltd. - Novartis AG - Nuvo Research Inc. - Oxagen Limited - Panacea Biotec Limited - Peptinnovate Limited - Pharmaxis Limited - Portola Pharmaceuticals, Inc. - Protectimmun GmbH - Pulmatrix, Inc. - Stallergenes S.A. - sterna biologicals Gmbh & Co KG - Swecure AB - The International Biotechnology Center (IBC) Generium - Verona Pharma Plc For more information visit http://www.researchandmarkets.com/research/68...gic_asthma
PTLA: 25.96 (+0.04), GSK: 45.07 (-0.11), PULM: 2.12 (-0.05), INFI: 1.68 (+0.06), ARRY: 3.74 (-0.03), NVS: 83.26 (+1.18)
Systemic Sclerosis (Scleroderma) Pipeline Review, H2 2015 - 24 Companies & 35 Drug Profiles
M2 - Fri Nov 06, 8:21AM CST
Research and Markets (http://www.researchandmarkets.com/research/v8xzj6/systemic) has announced the addition of the "Systemic Sclerosis (Scleroderma) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Systemic Sclerosis (Scleroderma), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Systemic Sclerosis (Scleroderma) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Allergan Plc - Angion Biomedica Corp. - arGentis Pharmaceuticals, LLC - Bayer AG - BioLineRx, Ltd. - BiOrion Technologies B.V. - Bristol-Myers Squibb Company - Celgene Corporation - Corbus pharmaceuticals, Inc. - CSL Limited - Daval International Limited - Digna Biotech, S.L. - F. Hoffmann-La Roche Ltd. - Fibrocell Science, Inc. - GlaxoSmithKline Plc - iBio, Inc. - Inventiva SAS - Kadmon Corporation, LLC - MedImmune, LLC - NovaLead Pharma Pvt. Ltd. - Peptinov SAS - Stratatech Corporation - Vida Therapeutics Inc. - VivaCell Biotechnology Espana S.L. Drug Profiles - abatacept - acALY-18 - Aimspro - ANG-3070 - ARG-201 - belimumab - BL-1110 - BOT-191 - C-82 - CC-220 - disitertide - factor XIII (human) - FCX-013 - GSK-2330811 - IBIOCFB-03 - inebilizumab - IVA-337 - JBT-101 - KD-025 - NLP-491 - Oligonucleotide for Scleroderma - onabotulinumtoxin A - P-17 - PAT-048 - PDX-002 - PPV-06 - riociguat - Small Molecule to Inhibit NFkB for Immunology and Oncology - Stem Cell Therapy for Crohns Disease, Systemic Sclerosis and Multiple Sclerosis - StrataGraft Skin Tissue - Synthetic Peptides to Inhibit TCR for Autoimmune Disorders and Dermatitis - tocilizumab - VCE-0048 - VEDA-1209 - VTI-1000 Series For more information visit http://www.researchandmarkets.com/research/v8xzj6/systemic
AGN: 252.95 (-2.61), FCSC: 1.09 (unch), IBIO: 0.61 (-0.02), GSK: 45.07 (-0.11), BMY: 74.81 (+0.15), CELGZ: 1.16 (-0.01)
NVS Influenza Vaccines Welcomes North Carolina Congresswoman Renee Ellmers on Tour of Holly Springs Manufacturing Facility
PR Newswire - Tue Oct 13, 8:38AM CDT
Yesterday Congresswoman Renee Ellmers (R-NC-02) visited the award-winning NVS Influenza Vaccines Holly Springs manufacturing site located in Holly Springs, NC.4 Since 2014, the facility has produced Flucelvax® (Influenza Vaccine) using cell-culture technology, a state-of-the-art production method that has the potential for faster start-up and is not reliant on chicken eggs.1,2 On July 31, 2015 CSL Limited acquired the influenza vaccines business of Novartis AG in the US, which for an interim period is referred to as NVS Influenza Vaccines.1
CSL: 103.29 (-0.67), NVS: 83.26 (+1.18)
Xencor's Partner begins Phase 2 clinical trial of biologic candidate using XmAb Cytotoxic Fc Domain
M2 - Fri Sep 25, 3:01AM CDT
Biopharmaceutical company Xencor (NasdaqGM:XNCR) disclosed on Thursday that it has begun a Phase 2 clinical trial for CSL362 (JNJ-56022473) using its XmAb Cytotoxic Fc Domain technology.
XNCR: 18.94 (+0.38)
FDA Advisory Panel Recommends Licensure of NVS Influenza Candidate Vaccine for Protection Against Seasonal Influenza in the Elderly
PR Newswire - Tue Sep 15, 12:40PM CDT
NVS Influenza Vaccines, now owned and operated by the CSL Limited, announced today that the Vaccines and Related Biological Products Advisory Committee (VRBPAC) of the US Food and Drug Administration (FDA) voted to recommend licensure of a candidate vaccine to help protect against seasonal influenza in those aged 65 years and older via accelerated approval. Currently under review by the FDA and if approved, the candidate vaccine would become the first adjuvanted seasonal influenza vaccine licensed for use in adults aged 65 and older in the US.1
NVS: 83.26 (+1.18)
